Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M52,047Revenue $M6,022Net Margin (%)58.6Altman Z-Score4.6
Enterprise Value $M146,515EPS $17.3Operating Margin %30.4Piotroski F-Score5
P/E(ttm)14.4Beneish M-Score-2.9Pre-tax Margin (%)57.4Higher ROA y-yY
Price/Book5.510-y EBITDA Growth Rate %--Quick Ratio0.4Cash flow > EarningsY
Price/Sales8.55-y EBITDA Growth Rate %27.7Current Ratio0.5Lower Leverage y-yY
Price/Free Cash Flow13.4y-y EBITDA Growth Rate %99.1ROA % (ttm)27.7Higher Current Ratio y-yN
Dividend Yield %0.3PEG0.5ROE % (ttm)50.2Less Shares Outstanding y-yN
Payout Ratio %4.0Shares Outstanding M200ROIC % (ttm)24.1Gross Margin Increase y-yN

Gurus Latest Trades with SHPG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SHPGFirst Eagle Investment 2015-03-31 Add0.12%$205.66 - $253.64
($229.81)
$ 260.1113%Add 254.93%294,539
SHPGLeon Cooperman 2015-03-31 Add0.1%$205.66 - $253.64
($229.81)
$ 260.1113%Add 5.70%500,192
SHPGMario Gabelli 2015-03-31 Sold Out -0.018%$205.66 - $253.64
($229.81)
$ 260.1113%Sold Out0
SHPGKen Fisher 2015-03-31 Add$205.66 - $253.64
($229.81)
$ 260.1113%Add 1.35%14,791
SHPGLeon Cooperman 2014-12-31 Buy 1.7%$170.49 - $262.71
($211.39)
$ 260.1123%New holding473,237
SHPGJohn Paulson 2014-12-31 Reduce-0.77%$170.49 - $262.71
($211.41)
$ 260.1123%Reduce 7.93%8,328,304
SHPGDavid Tepper 2014-12-31 Sold Out -0.71%$170.49 - $262.71
($211.58)
$ 260.1123%Sold Out0
SHPGFirst Eagle Investment 2014-12-31 Add0.04%$170.49 - $262.71
($211.58)
$ 260.1123%Add 453.24%82,986
SHPGMario Gabelli 2014-12-31 Reduce-0.03%$170.49 - $262.71
($211.58)
$ 260.1123%Reduce 57.13%16,225
SHPGKen Fisher 2014-12-31 Add0.01%$170.49 - $262.71
($211.58)
$ 260.1123%Add 416.24%14,594
SHPGJohn Paulson 2014-09-30 Add6.09%$231.98 - $262.64
($248.14)
$ 260.115%Add 168.70%9,046,000
SHPGDavid Tepper 2014-09-30 Buy 0.71%$231.98 - $262.64
($248.14)
$ 260.115%New holding185,944
SHPGMario Gabelli 2014-09-30 Buy 0.05%$231.98 - $262.64
($248.14)
$ 260.115%New holding37,850
SHPGFirst Eagle Investment 2014-09-30 Buy 0.01%$231.98 - $262.64
($248.14)
$ 260.115%New holding15,000
SHPGKen Fisher 2014-09-30 Reduce$231.98 - $262.64
($248.14)
$ 260.115%Reduce 39.56%2,827
SHPGJohn Paulson 2014-06-30 Add0.84%$142.83 - $234.98
($172.9)
$ 260.1150%Add 33.07%3,366,539
SHPGKen Fisher 2014-06-30 Add$142.83 - $234.98
($172.9)
$ 260.1150%Add 91.13%4,677
SHPGJohn Paulson 2013-12-31 Reduce-0.24%$113.87 - $140.87
($131.38)
$ 260.1198%Reduce 11.03%2,529,854
SHPGJohn Paulson 2013-06-30 Add0.98%$86.59 - $99.85
($93.74)
$ 260.11177%Add 107.43%2,843,500
SHPGMario Gabelli 2013-03-31 Sold Out -0.003%$89.83 - $101.63
($95.88)
$ 260.11171%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SHPG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SHPG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about SHPG :

    Quarterly/Annual Reports about SHPG:

    News about SHPG:

    Articles On GuruFocus.com
    8 Top Healthcare Stocks to Watch May 13 2015 
    John Paulson's Stocks Trading at Low P/E May 04 2015 
    Shire Reports A Good Quarter Promoted By Drug Sales May 03 2015 
    Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
    AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
    Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
    Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
    Pioneer Investments Purchases Time Warner Cable, Kohl's in Q4 Feb 10 2015 
    AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
    Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 

    More From Other Websites
    Can Gilead keep growing without a big deal? May 23 2015
    5 Investments That Show John Paulson Knows How to Play M&A May 22 2015
    Could M&A Boost Pfizer More? Jefferies Thinks So May 22 2015
    All Eyes on Pfizer as Shareholders Await the Mega-Deal: Real M&A May 21 2015
    Can video game playing end ADHD drug reliance? May 21 2015
    Healthcare Winners and Losers: May 19, 2015 May 19 2015
    Shire Has Outperformed AstraZeneca After Acquisition Bids For Both Failed To Materialize May 19 2015
    5 Big Pharma Stocks to Trade for Breakout Gains May 19 2015
    Circassia £275m fundraising signals revival of UK biotech sector May 19 2015
    Synergy Rallies 18% Following News of Paulson & Co. Stake May 18 2015
    John Paulson Continues To Bet On Health Care And TV May 17 2015
    Shire Recognizes HAE Day with Launch of Interactive Website Calling for Inspirational Wishes May 15 2015
    3 Shares Analysts Love: Lloyds Banking Group PLC, Shire PLC And Boohoo.Com PLC May 13 2015
    SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits May 12 2015
    Block Listing Application May 12 2015
    On the move: New hires and appointments in the local life sciences industry May 11 2015
    Shire to Present New Research at American Psychiatric Association Annual Meeting May 11 2015
    4 Top Jefferies Growth Stock Calls for This Week May 11 2015
    Shire to Present New Research at American Psychiatric Association Annual Meeting May 11 2015
    Jeff Poulton appointed as Chief Financial Officer - Principle terms of remuneration May 06 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK